Brainstorm Cell Therapeutics ( (BCLI) ) has released its Q2 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BrainStorm Cell Therapeutics Inc. is a pioneering company in the biotechnology sector, focusing on the development of autologous adult stem cell therapies for neurodegenerative diseases. Their flagship product, NurOwn, is an investigational therapy aimed at treating amyotrophic lateral sclerosis (ALS), leveraging a proprietary platform to modulate neuroinflammation and promote neuroprotection.
In its latest earnings report for the second quarter of 2025, BrainStorm Cell Therapeutics highlighted significant progress in its clinical development plans. The company received FDA clearance to initiate a Phase 3b trial for NurOwn, marking an important step towards a potential Biologics License Application (BLA) submission. Additionally, the company is actively engaging with clinical sites and contract development and manufacturing organizations to ensure readiness for clinical drug supply.
The financial results for the quarter showed a net loss of approximately $2.9 million, a slight improvement from the previous year’s loss of $2.5 million. Research and development expenses increased to $1.1 million, reflecting the company’s continued investment in advancing its clinical trials. General and administrative expenses decreased to $1.4 million, indicating a more efficient operational structure. Notably, BrainStorm’s cash position stood at $1.03 million as of June 30, 2025.
Strategically, BrainStorm has signed a Letter of Intent with Minaris Advanced Therapies to manufacture NurOwn for the upcoming trial, and new survival data from the Expanded Access Program showed promising results, with 100% of participants surviving more than five years from the onset of ALS symptoms. These developments underscore BrainStorm’s commitment to advancing its therapeutic offerings and addressing critical challenges in ALS treatment.
Looking ahead, BrainStorm Cell Therapeutics remains focused on executing its clinical development plans and engaging with the ALS community and regulatory bodies. The management is optimistic about NurOwn’s potential to make a meaningful impact on patients’ lives, contingent upon successful trial outcomes and regulatory approvals.